Protamine Sulfate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Protamine Sulfate
- Protamine Sulfate: From Heparin Reversal to Self-Limited Neonatal/Infantile Seizures
Protamine Sulfate: From Heparin Reversal to Self-Limited Neonatal/Infantile Seizures
One-Sentence Summary
Protamine sulfate is an injectable polycationic peptide used clinically to neutralise heparin. The TxGNN model lists self-limited familial and non-familial neonatal/infantile seizures as its top predicted new indication, but with a score of only 0.5 (uninformative), no clinical trials and no supporting publications. The evidence for this prediction is model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (protamine sulfate is generally known as a heparin-reversal agent) |
| Predicted New Indication | Self-limited familial and non-familial neonatal/infantile seizures |
| TxGNN Prediction Score | 50% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this report. Based on general knowledge, protamine sulfate is a heparin-neutralising polycationic peptide. Its efficacy in reversing heparin anticoagulation is well established, but it has no known antiseizure activity.
No plausible mechanistic link to neonatal or infantile seizures was identified. A score of 0.5 carries essentially no discriminating information, and no trials or literature support the prediction. Protamine also does not readily cross the blood-brain barrier, which further weakens any neurological rationale.
Other predicted indications show the same pattern. All were ranked with a score of 0.5, and none has trials or supportive literature:
| Rank | Predicted Indication | Evidence Level | Assessment |
|---|---|---|---|
| 2 | Immune epilepsy | L5 | No link to neuroimmune pathways; poor CNS penetration |
| 3 | Hypereosinophilia of undetermined significance | L5 | No known effect on eosinophil production or survival |
| 4 | PRPS1 deficiency disorder | L5 | No interaction with purine/nucleotide synthesis |
| 5 | Pericytoma with t(7;12) | L5 | No link to this rare fusion-driven tumour |
| 6 | Tyrosine hydroxylase deficiency | L5 | No action on catecholamine biosynthesis |
| 7 | TH-deficient infantile parkinsonism and motor delay | L5 | No dopaminergic or neurological mechanism |
| 8 | Anaphylaxis | L4 | Literature shows protamine causes anaphylaxis; harm signal, not therapeutic |
| 9 | Acetazolamide-responsive hereditary episodic ataxia | L5 | No ion-channel activity relevant to the condition |
| 10 | Idiopathic mast cell activation syndrome | L5 | Protamine can trigger mast cell degranulation; potential harm |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature supports the top-ranked prediction (neonatal/infantile seizures).
The only predicted indication with publications is anaphylaxis (rank 8). These papers describe protamine as a cause of anaphylaxis, not a treatment, so they represent a safety signal rather than evidence for repurposing. Representative examples:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18816305 | 2008 | Systematic review | Basic Clin Pharmacol Toxicol | Systematic review of serious anaphylactic reactions to protamine, mainly in cardiac surgery |
| 1831070 | 1991 | Cohort | Cathet Cardiovasc Diagn | Risk of protamine allergy reactions in patients using protamine-insulin preparations, assessed across 7,750 catheterisations |
| 37172213 | 2023 | Review | Catheter Cardiovasc Interv | Contemporary role of protamine for heparin reversal in the cardiac catheterisation laboratory |
| 2857186 | 1985 | Review | J Allergy Clin Immunol | Serious adverse reactions to protamine and the question of alternatives |
| 10580216 | 1999 | Review | Heart & Lung | Type I anaphylactic reaction to protamine and associated risk factors |
| 39350802 | 2024 | Case report | Cureus | Anaphylaxis with profound hypotension during carotid endarterectomy; confirmed by elevated tryptase |
| 3366061 | 1988 | Case report | Drug Intell Clin Pharm | Fatal anaphylactoid shock after protamine reversal of heparin following bypass surgery |
| 621346 | 1978 | Study | J Allergy Clin Immunol | Anaphylaxis mediated by a complement-dependent IgG antibody; prior protamine exposure raises risk |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03696P | PROSULF INJECTION 1% (CP Pharmaceuticals Ltd) | Injection | Not stated in the licence record |
Safety Considerations
- Hypersensitivity and anaphylaxis: The literature compiled for this report consistently describes serious, sometimes fatal, anaphylactic or anaphylactoid reactions to protamine. Reported risk factors include prior exposure to protamine-containing insulin (NPH), fish allergy, vasectomy, and previous protamine exposure. Reactions can also occur without identifiable risk factors.
- Mast cell activation: Protamine is a polycationic peptide that can trigger mast cell degranulation and histamine release.
For other safety information, including formal warnings, contraindications and drug interactions, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: All predictions are computational only, with uninformative scores (0.5), no clinical trials, and no plausible mechanistic link. The only indication with literature (anaphylaxis) shows protamine as a cause of harm, not a treatment.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator, to enable safety screening
- Mechanism of action data for protamine sulfate
- The approved indication text for the Singapore licence
- A credible mechanistic hypothesis and preclinical evidence for any candidate indication before further evaluation
- Reassessment of the model predictions, since a flat score of 0.5 across all candidates suggests low model confidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.